Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 8, 2014, Pages 2148-2154

  Snyder, Ashley Hall ^a   Werth, Brian J ^a,b   Barber, Katie E ^a   Sakoulas, George ^c,d   Rybak, Michael J ^a,e  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SAN DIEGO   (United States)

^d SHARP MEMORIAL HOSPITAL   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Combination therapy; Endocarditis; Enterococcus faecalis; Enterococcus faecium

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; DAPTOMYCIN; FLUORESCEIN ISOTHIOCYANATE; POLYLYSINE; ANTIINFECTIVE AGENT; VANCOMYCIN;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BROTH DILUTION; CELL SURFACE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; ENDOCARDIUM; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; ISOTOPE LABELING; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; SIMULATED ENDOCARDIAL VEGETATION; SURFACE CHARGE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VEGETATION; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

AMPICILLIN; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN; VANCOMYCIN RESISTANCE; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84904569642     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku113     Document Type: Article

References (35)

1. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45: 601-8.
2. Johnson AP, Mushtaq S, Warner M et al. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int J Antimicrob Agents 2004; 24: 315-9.
3. Anastasiou DM, Thorne GM, Luperchio SA et al. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006; 28: 385-8.
4. Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis 2009; 65: 158-62.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
6. Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol 2009; 30: 184-6.
7. Kelesidis T, Humphries R, Uslan DZ et al. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011; 52: 228-34.
8. Biedenbach DJ, Bell JM, Sader HS et al. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int J Antimicrob Agents 2007; 30: 143-9.
9. Fluit AC, Schmitz FJ, Verhoef J et al. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Int J Antimicrob Agents 2004; 24: 59-66.
10. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-434.
11. Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J Chemother 2006; 18: 27-32.
12. Arias CA, Torres HA, Singh KV et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007; 45: 1343-6.
13. Munita J, Reyes J, Tran T et al. Sub inhibitory concentrations of ceftriaxone revert daptomycin resistance in Enterococcus faecalis. In: Abstracts of the Second ID Week, San Francisco, CA, USA, 2013. Abstract 1136, p. 48. Infectious Diseases Society of America, Arlington, VA, USA.
14. Moise PA, Lamp KC, DePestel DD et al. Daptomycin with or without concomitant β-lactams for vancomycin-resistant enterococcus bacteremia. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract K-276, p. 53. American Society for Microbiology, Washington, DC, USA.
15. Sakoulas G, Bayer AS, Pogliano J et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56: 838-44.
16. Werth BJ, Sakoulas G, Rose WE et al. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycinnonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013; 57: 66-73.
17. Dhand A, Bayer AS, Pogliano J et al. Use of antistaphylococcal β-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53: 158-63.
18. Rose WE, Schulz LT, Andes D et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012; 56: 5296-302.
19. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005; 49: 2735-45.
20. Benvenuto M, Benziger DP, Yankelev S et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245-9.
21. Patel IH, Chen S, Parsonnet M et al. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother 1981; 20: 634-41.
22. Blaser J. In vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 1985; 15 Suppl A: 125-30.
23. Martens-Lobenhoffer J, Kielstein JT, Oye C et al. Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 875: 546-50.
24. Kullar R, Chin JN, Edwards DJ et al. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother 2011; 55: 3505-9.
25. Dvorchik BH, Brazier D, DeBruin MFet al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-23.
26. Goudah A, Shin HC, Shim JH et al. Characterization of the relationship between serum and milk residue disposition of ceftriaxone in lactating ewes. J Vet Pharmacol Ther 2006; 29: 307-12.
27. Pletz MW, Rau M, Bulitta J et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48: 3765-72.
28. Jones T, Yeaman MR, Sakoulas G et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52: 269-78.
29. Richaud C, Chau F, Sotier M et al. Impact of reduced susceptibility to daptomycin in Enterococcus faecium on daptomycin activity in vitro and in vivo. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract B-660, p. 89. American Society for Microbiology, Washington, DC, USA.
30. Pettit N, Brielmaier B, Mawdsley EL et al. Reduced daptomycin susceptibility (MIC 3-4 mg/mL) among vancomycin-resistant enterococci bloodstream isolates. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract K-279, p. 53. American Society for Microbiology, Washington, DC, USA.
31. Kelesidis T, Tsiodras S, Humphries R. Case series of daptomycin nonsusceptible enterococcus urinary tract infections in a tertiary center. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract K-280, p. 53. American Society for Microbiology, Washington, DC, USA.
32. Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003; 47: 539-46.
33. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003; 47: 1598-603.
34. Hall AD, Steed ME, Arias CA et al. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2012; 56: 3174-80.
35. Werth BJ, Steed ME, Ireland CE et al. Defining daptomycin mutant prevention exposures in vancomycin-resistant Enterococcus faecium and faecalis. In: Abstracts of the Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, USA, 2013. Abstract A-020, p. 37. American Society for Microbiology, Washington, DC, USA.